| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Activation of the PI3K/Akt pathway and chemotherapeutic resistance
|
West, Kip A
|
|
2002
|
21-22 |
6 |
p. 234-248
15 p.
|
artikel
|
| 2 |
Active transport of siderophore-mimicking antibacterials across the outer membrane
|
Braun, Volkmar
|
|
1999
|
21-22 |
6 |
p. 363-369
7 p.
|
artikel
|
| 3 |
Altering protein turnover in tumor cells: New opportunities for anti-cancer therapies
|
Demarchi, Francesca
|
|
2005
|
21-22 |
6 |
p. 359-368
10 p.
|
artikel
|
| 4 |
Aminoglycoside modifying enzymes
|
Ramirez, Maria S.
|
|
2010
|
21-22 |
6 |
p. 151-171
21 p.
|
artikel
|
| 5 |
An ABC-type multidrug transporter of Lactococcus lactis possesses an exceptionally broad substrate specificity
|
Poelarends, Gerrit J.
|
|
2000
|
21-22 |
6 |
p. 330-334
5 p.
|
artikel
|
| 6 |
Anticancer therapy with novel tubulin-interacting drugs
|
Kavallaris, Maria
|
|
2001
|
21-22 |
6 |
p. 392-401
10 p.
|
artikel
|
| 7 |
Anti-growth factor therapy for lung cancer
|
Chan, Daniel C.
|
|
1998
|
21-22 |
6 |
p. 377-388
12 p.
|
artikel
|
| 8 |
Apoptosis assays for quantifying the bioactivity of anticancer drug products
|
Brunelle, Joslyn K.
|
|
2010
|
21-22 |
6 |
p. 172-179
8 p.
|
artikel
|
| 9 |
Azole-resistance in Aspergillus: Proposed nomenclature and breakpoints
|
Verweij, Paul E.
|
|
2009
|
21-22 |
6 |
p. 141-147
7 p.
|
artikel
|
| 10 |
BH3 mimetics to improve cancer therapy; mechanisms and examples
|
Zhang, Lin
|
|
2007
|
21-22 |
6 |
p. 207-217
11 p.
|
artikel
|
| 11 |
Breakpoints for antifungal agents: An update from EUCAST focussing on echinocandins against Candida spp. and triazoles against Aspergillus spp.
|
Arendrup, Maiken C.
|
|
2013
|
21-22 |
6 |
p. 81-95
15 p.
|
artikel
|
| 12 |
Cancer cell death by programmed necrosis?
|
Borst, Piet
|
|
2004
|
21-22 |
6 |
p. 321-324
4 p.
|
artikel
|
| 13 |
Cell cycle regulatory E3 ubiquitin ligases as anticancer targets
|
Pray, Todd R
|
|
2002
|
21-22 |
6 |
p. 249-258
10 p.
|
artikel
|
| 14 |
Chemotherapeutic potential of the chemopreventive phytoalexin resveratrol
|
Pervaiz, Shazib
|
|
2004
|
21-22 |
6 |
p. 333-344
12 p.
|
artikel
|
| 15 |
Chloroquine resistance and the pH of the malaria parasite's digestive vacuole
|
Kirk, Kiaran
|
|
2001
|
21-22 |
6 |
p. 335-338
4 p.
|
artikel
|
| 16 |
Contents, Author and Keyword Indices
|
|
|
2004
|
21-22 |
6 |
p. I-VIII
nvt p.
|
artikel
|
| 17 |
Defects of the apoptotic pathway as therapeutic target against cancer
|
Mashima, Tetsuo
|
|
2005
|
21-22 |
6 |
p. 339-343
5 p.
|
artikel
|
| 18 |
Dihydrofolate reductase and antifolate resistance in malaria
|
Sirawaraporn, Worachart
|
|
1998
|
21-22 |
6 |
p. 397-406
10 p.
|
artikel
|
| 19 |
DNA methylation and cancer therapy
|
Szyf, Moshe
|
|
2003
|
21-22 |
6 |
p. 341-353
13 p.
|
artikel
|
| 20 |
Does P-glycoprotein play a role in anticancer drug pharmacokinetics?
|
Sparreboom, Alex
|
|
2000
|
21-22 |
6 |
p. 357-363
7 p.
|
artikel
|
| 21 |
Drug-resistant tuberculosis in the WHO European Region: An analysis of surveillance data
|
Zignol, Matteo
|
|
2013
|
21-22 |
6 |
p. 108-115
8 p.
|
artikel
|
| 22 |
Drug treatment of microsporidiosis
|
Costa, Sylvia F.
|
|
2000
|
21-22 |
6 |
p. 384-399
16 p.
|
artikel
|
| 23 |
Editorial Board
|
|
|
2009
|
21-22 |
6 |
p. i-
1 p.
|
artikel
|
| 24 |
Editorial Board
|
|
|
2010
|
21-22 |
6 |
p. i-
1 p.
|
artikel
|
| 25 |
Editorial Board
|
|
|
2013
|
21-22 |
6 |
p. i-
1 p.
|
artikel
|
| 26 |
Editorial Board
|
|
|
2002
|
21-22 |
6 |
p. i-
1 p.
|
artikel
|
| 27 |
Editorial Board
|
|
|
2003
|
21-22 |
6 |
p. i-
1 p.
|
artikel
|
| 28 |
Editorial Board
|
|
|
2006
|
21-22 |
6 |
p. i-
1 p.
|
artikel
|
| 29 |
Editorial Board
|
|
|
2004
|
21-22 |
6 |
p. i-
1 p.
|
artikel
|
| 30 |
Editorial Board
|
|
|
2007
|
21-22 |
6 |
p. i-
1 p.
|
artikel
|
| 31 |
Editorial Board
|
|
|
2005
|
21-22 |
6 |
p. i-
1 p.
|
artikel
|
| 32 |
Editorial Board
|
|
|
2008
|
21-22 |
6 |
p. i-
1 p.
|
artikel
|
| 33 |
Editorial Board
|
|
|
2011
|
21-22 |
6 |
p. i-
1 p.
|
artikel
|
| 34 |
Effects of HER-2/neu on chemosensitivity of tumor cells
|
Järvinen, Tero A.H.
|
|
2000
|
21-22 |
6 |
p. 319-324
6 p.
|
artikel
|
| 35 |
Epigenetics and chemoresistance in colorectal cancer: An opportunity for treatment tailoring and novel therapeutic strategies
|
Crea, Francesco
|
|
2011
|
21-22 |
6 |
p. 280-296
17 p.
|
artikel
|
| 36 |
Experimental evolution as an efficient tool to dissect adaptive paths to antibiotic resistance
|
Jansen, Gunther
|
|
2013
|
21-22 |
6 |
p. 96-107
12 p.
|
artikel
|
| 37 |
Fitness of drug resistant HIV-1: methodology and clinical implications
|
Quiñones-Mateu, Miguel E
|
|
2002
|
21-22 |
6 |
p. 224-233
10 p.
|
artikel
|
| 38 |
Five-fold increase in Trypanosoma congolense isolates resistant to diminazene aceturate over a seven-year period in Eastern Zambia
|
Delespaux, Vincent
|
|
2008
|
21-22 |
6 |
p. 205-209
5 p.
|
artikel
|
| 39 |
HIV drug resistance and implications for the introduction of antiretroviral therapy in resource-poor countries
|
Petrella, Marco
|
|
2001
|
21-22 |
6 |
p. 339-346
8 p.
|
artikel
|
| 40 |
HIV mutagenesis and the evolution of antiretroviral drug resistance
|
Mansky, Louis M.
|
|
2002
|
21-22 |
6 |
p. 219-223
5 p.
|
artikel
|
| 41 |
Individualized chemotherapy treatment for breast cancer: is it necessary? Is it feasible?
|
Pusztai, Lajos
|
|
2004
|
21-22 |
6 |
p. 325-331
7 p.
|
artikel
|
| 42 |
Lessons from TRAIL-resistance mechanisms in colorectal cancer cells: paving the road to patient-tailored therapy
|
Van Geelen, Caroline M.M.
|
|
2004
|
21-22 |
6 |
p. 345-358
14 p.
|
artikel
|
| 43 |
Literature highlights
|
|
|
2003
|
21-22 |
6 |
p. 373-375
3 p.
|
artikel
|
| 44 |
Literature highlights - 9/6 Recent research in infectious disease drug resistance
|
|
|
2006
|
21-22 |
6 |
p. 307-320
14 p.
|
artikel
|
| 45 |
Literature Highlights - 10/6 Recent research in infectious disease drug resistance
|
|
|
2007
|
21-22 |
6 |
p. 256-264
9 p.
|
artikel
|
| 46 |
Literature highlights: Recent research in infectious disease drug resistance
|
|
|
2005
|
21-22 |
6 |
p. 403-410
8 p.
|
artikel
|
| 47 |
Literature highlights: recent research in infectious disease drup resistance
|
|
|
2004
|
21-22 |
6 |
p. 359-366
8 p.
|
artikel
|
| 48 |
Mechanism of action of 2-methoxyestradiol: new developments
|
Mooberry, Susan L.
|
|
2003
|
21-22 |
6 |
p. 355-361
7 p.
|
artikel
|
| 49 |
Mechanisms and clinical prospects of Notch inhibitors in the therapy of hematological malignancies
|
Nefedova, Yulia
|
|
2008
|
21-22 |
6 |
p. 210-218
9 p.
|
artikel
|
| 50 |
Mechanisms of resistance to rapamycins
|
Huang, Shile
|
|
2001
|
21-22 |
6 |
p. 378-391
14 p.
|
artikel
|
| 51 |
Meetings Calendar
|
|
|
2009
|
21-22 |
6 |
p. A1-
1 p.
|
artikel
|
| 52 |
Meetings Calendar
|
|
|
2000
|
21-22 |
6 |
p. 401-404
4 p.
|
artikel
|
| 53 |
Meetings calendar
|
|
|
1998
|
21-22 |
6 |
p. 411-412
2 p.
|
artikel
|
| 54 |
Meetings Calendar
|
|
|
1999
|
21-22 |
6 |
p. 415-417
3 p.
|
artikel
|
| 55 |
Meetings Calendar
|
|
|
2006
|
21-22 |
6 |
p. 321-322
2 p.
|
artikel
|
| 56 |
Meetings Calendar
|
|
|
2007
|
21-22 |
6 |
p. 265-
1 p.
|
artikel
|
| 57 |
Meetings Calendar
|
|
|
2008
|
21-22 |
6 |
p. 254-256
3 p.
|
artikel
|
| 58 |
Mining bacterial cell wall biosynthesis with new tools: multitarget screens
|
Trias, Joaquim
|
|
1999
|
21-22 |
6 |
p. 358-362
5 p.
|
artikel
|
| 59 |
Modulating protein kinase C (PKC) to increase the efficacy of chemotherapy: stepping into darkness
|
Lorenzo, Patricia S
|
|
2003
|
21-22 |
6 |
p. 329-339
11 p.
|
artikel
|
| 60 |
Molecular aspects of azole antifungal action and resistance
|
Lamb, David
|
|
1999
|
21-22 |
6 |
p. 390-402
13 p.
|
artikel
|
| 61 |
Molecular mechanisms of resistance to taxanes and therapeutic implications
|
Zunino, Franco
|
|
1999
|
21-22 |
6 |
p. 351-357
7 p.
|
artikel
|
| 62 |
New directions in cancer research 2003: technological advances in biology, drug resistance, and molecular pharmacology
|
Franks, Michael E
|
|
2003
|
21-22 |
6 |
p. 301-312
12 p.
|
artikel
|
| 63 |
Novel strategies for reversing platinum resistance
|
Shahzad, Mian M.K.
|
|
2009
|
21-22 |
6 |
p. 148-152
5 p.
|
artikel
|
| 64 |
One, two, three—p53, p63, p73 and chemosensitivity
|
Müller, Martina
|
|
2006
|
21-22 |
6 |
p. 288-306
19 p.
|
artikel
|
| 65 |
Overcoming apoptosis deficiency of melanoma—Hope for new therapeutic approaches
|
Eberle, Jürgen
|
|
2007
|
21-22 |
6 |
p. 218-234
17 p.
|
artikel
|
| 66 |
Parameters for individualizing systemic therapy in non-small cell lung cancer
|
Gadgeel, Shirish M.
|
|
2010
|
21-22 |
6 |
p. 196-204
9 p.
|
artikel
|
| 67 |
PARP inhibitors in cancer therapy: Two modes of attack on the cancer cell widening the clinical applications
|
Drew, Yvette
|
|
2009
|
21-22 |
6 |
p. 153-156
4 p.
|
artikel
|
| 68 |
Perspectives for cancer therapies with cdk2 inhibitors
|
Wadler, Scott
|
|
2001
|
21-22 |
6 |
p. 347-367
21 p.
|
artikel
|
| 69 |
P. falciparum dihydrofolate reductase and dihydropteroate synthase mutations: epidemiology and role in clinical resistance to antifolates
|
Plowe, Christopher V.
|
|
1998
|
21-22 |
6 |
p. 389-396
8 p.
|
artikel
|
| 70 |
p53 family members and chemoresistance in cancer: what we know and what we need to know
|
Gasco, Milena
|
|
2003
|
21-22 |
6 |
p. 323-328
6 p.
|
artikel
|
| 71 |
Phenotypic antibiotic tolerance of Staphylococcus aureus in implant-related infections: relationship with in vitro colonization of artificial surfaces
|
Vaudaux, Pierre
|
|
1998
|
21-22 |
6 |
p. 352-357
6 p.
|
artikel
|
| 72 |
Photoaffinity analogs for multidrug resistance-related transporters and their use in identifying chemosensitizers
|
Safa, Ahmad R.
|
|
1999
|
21-22 |
6 |
p. 371-381
11 p.
|
artikel
|
| 73 |
Protein-intrinsic and signaling network-based sources of resistance to EGFR- and ErbB family-targeted therapies in head and neck cancer
|
Mehra, Ranee
|
|
2011
|
21-22 |
6 |
p. 260-279
20 p.
|
artikel
|
| 74 |
Rac signaling in tumorigenesis and as target for anticancer drug development
|
Sun, Di
|
|
2006
|
21-22 |
6 |
p. 274-287
14 p.
|
artikel
|
| 75 |
Recent research in infectious disease drug resistance
|
|
|
2008
|
21-22 |
6 |
p. 247-253
7 p.
|
artikel
|
| 76 |
Regulation of pleiotropic drug resistance in yeast
|
Kolaczkowska, Anna
|
|
1999
|
21-22 |
6 |
p. 403-414
12 p.
|
artikel
|
| 77 |
Reversing drug resistance in bcl-2-expressing tumor cells by depleting glutathione
|
Voehringer, D.W.
|
|
1998
|
21-22 |
6 |
p. 345-351
7 p.
|
artikel
|
| 78 |
RGD-based strategies for selective delivery of therapeutics and imaging agents to the tumour vasculature
|
Temming, Kai
|
|
2005
|
21-22 |
6 |
p. 381-402
22 p.
|
artikel
|
| 79 |
Role of the microenvironment in tumor growth and in refractoriness/resistance to anti-angiogenic therapies
|
Shojaei, Farbod
|
|
2008
|
21-22 |
6 |
p. 219-230
12 p.
|
artikel
|
| 80 |
Selective targeting of cancer cells using synthetic peptides
|
Shadidi, Mohsen
|
|
2003
|
21-22 |
6 |
p. 363-371
9 p.
|
artikel
|
| 81 |
Slipping and sliding: Frameshift mutations in herpes simplex virus thymidine kinase and drug-resistance
|
Griffiths, Anthony
|
|
2011
|
21-22 |
6 |
p. 251-259
9 p.
|
artikel
|
| 82 |
SPARC in cancer biology: Its role in cancer progression and potential for therapy
|
Tai, Isabella T.
|
|
2008
|
21-22 |
6 |
p. 231-246
16 p.
|
artikel
|
| 83 |
Sphingolipid metabolism, apoptosis and resistance to cytotoxic agents: can we interfere?
|
Rizzieri, Kellie E.
|
|
1998
|
21-22 |
6 |
p. 359-376
18 p.
|
artikel
|
| 84 |
Sterol biosynthesis in Pneumocystis: unique steps that define unique targets
|
Kaneshiro, Edna S.
|
|
2002
|
21-22 |
6 |
p. 259-268
10 p.
|
artikel
|
| 85 |
Tailoring Ras-pathway—Inhibitor combinations for cancer therapy
|
Blum, Roy
|
|
2005
|
21-22 |
6 |
p. 369-380
12 p.
|
artikel
|
| 86 |
10th Conference on DNA Topoisomerases in therapy
|
Giaccone, Giuseppe
|
|
1999
|
21-22 |
6 |
p. 347-350
4 p.
|
artikel
|
| 87 |
The importance of p53 location: nuclear or cytoplasmic zip code?
|
O’Brate, Aurora
|
|
2003
|
21-22 |
6 |
p. 313-322
10 p.
|
artikel
|
| 88 |
The proteasome as a potential target for novel anticancer drugs and chemosensitizers
|
Landis-Piwowar, Kristin R.
|
|
2006
|
21-22 |
6 |
p. 263-273
11 p.
|
artikel
|
| 89 |
Therapeutic potential of AIF-mediated caspase-independent programmed cell death
|
Lorenzo, Hans K.
|
|
2007
|
21-22 |
6 |
p. 235-255
21 p.
|
artikel
|
| 90 |
The relevance of drug sequence in combination chemotherapy
|
Shah, Manish A.
|
|
2000
|
21-22 |
6 |
p. 335-356
22 p.
|
artikel
|
| 91 |
The role of efflux in macrolide resistance
|
Zhong, Ping
|
|
2000
|
21-22 |
6 |
p. 325-329
5 p.
|
artikel
|
| 92 |
The role of murine models in the development of antifungal therapy for systemic mycoses
|
Graybill, John R.
|
|
2000
|
21-22 |
6 |
p. 364-383
20 p.
|
artikel
|
| 93 |
38th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) San Diego, USA, 24–27 September 1998
|
Georgopapadakou, Nafsika H.
|
|
1998
|
21-22 |
6 |
p. 407-409
3 p.
|
artikel
|
| 94 |
Tumor cell resistance to DNA topoisomerase II inhibitors: new developments
|
Beck, William T.
|
|
1999
|
21-22 |
6 |
p. 382-389
8 p.
|
artikel
|
| 95 |
Update on antifungal drug resistance mechanisms of Aspergillus fumigatus
|
Chamilos, G.
|
|
2005
|
21-22 |
6 |
p. 344-358
15 p.
|
artikel
|
| 96 |
Updates on functions of ceramide in chemotherapy-induced cell death and in multidrug resistance
|
Ogretmen, Besim
|
|
2001
|
21-22 |
6 |
p. 368-377
10 p.
|
artikel
|
| 97 |
Volume contents
|
|
|
1998
|
21-22 |
6 |
p. i-iv
nvt p.
|
artikel
|
| 98 |
Volume contents, Subject and Author Index Volume 5 2002
|
|
|
2002
|
21-22 |
6 |
p. I-XII
nvt p.
|
artikel
|
| 99 |
Wild-type MIC distributions, epidemiological cutoff values and species-specific clinical breakpoints for fluconazole and Candida: Time for harmonization of CLSI and EUCAST broth microdilution methods
|
Pfaller, M.A.
|
|
2010
|
21-22 |
6 |
p. 180-195
16 p.
|
artikel
|
Tijdschrift beschrijving